Literature DB >> 21632761

Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms.

Emilie Battivelli1, Julie Migraine, Denise Lecossier, Saori Matsuoka, Danielle Perez-Bercoff, Sentob Saragosti, François Clavel, Allan J Hance.   

Abstract

TRIM5α is a restriction factor that can block an early step in the retroviral life cycle by recognizing and causing the disassembly of incoming viral capsids, thereby preventing the completion of reverse transcription. Numerous other isoforms of human TRIM5 exist, and isoforms lacking a C-terminal SPRY domain can inhibit the activity of TRIM5α. Thus, TRIM5α activity in a given cell type could be dependent on the relative proportions of TRIM5 isoforms expressed, but little information concerning the relative expression of TRIM5 isoforms in human cells is available. In this study, we demonstrate that mRNAs coding for TRIM5α represent only 50% of total TRIM5 transcripts in human cell lines, CD4(+) T cells, and macrophages. Transcripts coding for, in order of abundance, TRIM5ι (TRIM5-iota), a previously uncharacterized isoform, TRIM5γ, TRIM5δ, and TRIM5κ are also present. Like TRIM5γ and TRIM5δ, TRIM5ι and TRIM5κ do not inhibit HIV-1 replication, but both have dominant-negative activity against TRIM5α. Specific knockdown of TRIM5ι increases TRIM5α activity in human U373-X4 cells, indicating that physiological levels of expression of truncated TRIM5 isoforms in human cells can reduce the activity of TRIM5α.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632761      PMCID: PMC3147942          DOI: 10.1128/JVI.00648-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Use of a transient assay for studying the genetic determinants of Fv1 restriction.

Authors:  M Bock; K N Bishop; G Towers; J P Stoye
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Alu-containing exons are alternatively spliced.

Authors:  Rotem Sorek; Gil Ast; Dan Graur
Journal:  Genome Res       Date:  2002-07       Impact factor: 9.043

3.  Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.

Authors:  Theodora Hatziioannou; David Perez-Caballero; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.

Authors:  Matthew Stremlau; Michel Perron; Sohanya Welikala; Joseph Sodroski
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues.

Authors:  Lionel Berthoux; Sarah Sebastian; David M Sayah; Jeremy Luban
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Trim5alpha protein restricts both HIV-1 and murine leukemia virus.

Authors:  Melvyn W Yap; Sébastien Nisole; Clare Lynch; Jonathan P Stoye
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

7.  The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.

Authors:  Zuzana Keckesova; Laura M J Ylinen; Greg J Towers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

8.  Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid.

Authors:  Theodora Hatziioannou; Simone Cowan; Uta K Von Schwedler; Wesley I Sundquist; Paul D Bieniasz
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

10.  The sequence of the human genome.

Authors:  J C Venter; M D Adams; E W Myers; P W Li; R J Mural; G G Sutton; H O Smith; M Yandell; C A Evans; R A Holt; J D Gocayne; P Amanatides; R M Ballew; D H Huson; J R Wortman; Q Zhang; C D Kodira; X H Zheng; L Chen; M Skupski; G Subramanian; P D Thomas; J Zhang; G L Gabor Miklos; C Nelson; S Broder; A G Clark; J Nadeau; V A McKusick; N Zinder; A J Levine; R J Roberts; M Simon; C Slayman; M Hunkapiller; R Bolanos; A Delcher; I Dew; D Fasulo; M Flanigan; L Florea; A Halpern; S Hannenhalli; S Kravitz; S Levy; C Mobarry; K Reinert; K Remington; J Abu-Threideh; E Beasley; K Biddick; V Bonazzi; R Brandon; M Cargill; I Chandramouliswaran; R Charlab; K Chaturvedi; Z Deng; V Di Francesco; P Dunn; K Eilbeck; C Evangelista; A E Gabrielian; W Gan; W Ge; F Gong; Z Gu; P Guan; T J Heiman; M E Higgins; R R Ji; Z Ke; K A Ketchum; Z Lai; Y Lei; Z Li; J Li; Y Liang; X Lin; F Lu; G V Merkulov; N Milshina; H M Moore; A K Naik; V A Narayan; B Neelam; D Nusskern; D B Rusch; S Salzberg; W Shao; B Shue; J Sun; Z Wang; A Wang; X Wang; J Wang; M Wei; R Wides; C Xiao; C Yan; A Yao; J Ye; M Zhan; W Zhang; H Zhang; Q Zhao; L Zheng; F Zhong; W Zhong; S Zhu; S Zhao; D Gilbert; S Baumhueter; G Spier; C Carter; A Cravchik; T Woodage; F Ali; H An; A Awe; D Baldwin; H Baden; M Barnstead; I Barrow; K Beeson; D Busam; A Carver; A Center; M L Cheng; L Curry; S Danaher; L Davenport; R Desilets; S Dietz; K Dodson; L Doup; S Ferriera; N Garg; A Gluecksmann; B Hart; J Haynes; C Haynes; C Heiner; S Hladun; D Hostin; J Houck; T Howland; C Ibegwam; J Johnson; F Kalush; L Kline; S Koduru; A Love; F Mann; D May; S McCawley; T McIntosh; I McMullen; M Moy; L Moy; B Murphy; K Nelson; C Pfannkoch; E Pratts; V Puri; H Qureshi; M Reardon; R Rodriguez; Y H Rogers; D Romblad; B Ruhfel; R Scott; C Sitter; M Smallwood; E Stewart; R Strong; E Suh; R Thomas; N N Tint; S Tse; C Vech; G Wang; J Wetter; S Williams; M Williams; S Windsor; E Winn-Deen; K Wolfe; J Zaveri; K Zaveri; J F Abril; R Guigó; M J Campbell; K V Sjolander; B Karlak; A Kejariwal; H Mi; B Lazareva; T Hatton; A Narechania; K Diemer; A Muruganujan; N Guo; S Sato; V Bafna; S Istrail; R Lippert; R Schwartz; B Walenz; S Yooseph; D Allen; A Basu; J Baxendale; L Blick; M Caminha; J Carnes-Stine; P Caulk; Y H Chiang; M Coyne; C Dahlke; A Deslattes Mays; M Dombroski; M Donnelly; D Ely; S Esparham; C Fosler; H Gire; S Glanowski; K Glasser; A Glodek; M Gorokhov; K Graham; B Gropman; M Harris; J Heil; S Henderson; J Hoover; D Jennings; C Jordan; J Jordan; J Kasha; L Kagan; C Kraft; A Levitsky; M Lewis; X Liu; J Lopez; D Ma; W Majoros; J McDaniel; S Murphy; M Newman; T Nguyen; N Nguyen; M Nodell; S Pan; J Peck; M Peterson; W Rowe; R Sanders; J Scott; M Simpson; T Smith; A Sprague; T Stockwell; R Turner; E Venter; M Wang; M Wen; D Wu; M Wu; A Xia; A Zandieh; X Zhu
Journal:  Science       Date:  2001-02-16       Impact factor: 47.728

View more
  20 in total

Review 1.  The role of human dendritic cells in HIV-1 infection.

Authors:  Zahra Ahmed; Tatsuyoshi Kawamura; Shinji Shimada; Vincent Piguet
Journal:  J Invest Dermatol       Date:  2014-11-19       Impact factor: 8.551

Review 2.  TRIMming p53's anticancer activity.

Authors:  S Elabd; G Meroni; C Blattner
Journal:  Oncogene       Date:  2016-02-22       Impact factor: 9.867

Review 3.  TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity.

Authors:  Ricardo Rajsbaum; Adolfo García-Sastre; Gijs A Versteeg
Journal:  J Mol Biol       Date:  2013-12-12       Impact factor: 5.469

4.  The TRIMCyp genotype in four species of macaques in China.

Authors:  Chang-Qing Yu; Lei Na; Xiao-Ling Lv; Jian-Dong Liu; Xiao-Ming Liu; Fang Ji; Yong-Hui Zheng; Hong-Li Du; Xian-Gang Kong; Jian-Hua Zhou
Journal:  Immunogenetics       Date:  2012-12-12       Impact factor: 2.846

5.  Dynamic Modulation of Expression of Lentiviral Restriction Factors in Primary CD4+ T Cells following Simian Immunodeficiency Virus Infection.

Authors:  Andrew R Rahmberg; Premeela A Rajakumar; James M Billingsley; R Paul Johnson
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

Review 6.  TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling.

Authors:  Markus G Grütter; Jeremy Luban
Journal:  Curr Opin Virol       Date:  2012-03-05       Impact factor: 7.090

Review 7.  Restriction of HIV-1 and other retroviruses by TRIM5.

Authors:  Barbie K Ganser-Pornillos; Owen Pornillos
Journal:  Nat Rev Microbiol       Date:  2019-07-16       Impact factor: 60.633

Review 8.  Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo.

Authors:  Eun Suk Lee; Carol A Rasmussen; Mark S Filla; Sarah R Slauson; Aaron W Kolb; Donna M Peters; Paul L Kaufman; B'Ann T Gabelt; Curtis R Brandt
Journal:  Curr Eye Res       Date:  2014-02-21       Impact factor: 2.424

9.  Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles.

Authors:  Clémence Granier; Emilie Battivelli; Camille Lécuroux; Alain Venet; Olivier Lambotte; Marion Schmitt-Boulanger; Constance Delaugerre; Jean-Michel Molina; Lisa A Chakrabarti; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

10.  Stabilized human TRIM5α protects human T cells from HIV-1 infection.

Authors:  Max W Richardson; Lili Guo; Frances Xin; Xiaolu Yang; James L Riley
Journal:  Mol Ther       Date:  2014-03-25       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.